Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Preimplantation Genetic Testing Market - Global Forecast 2026-2032 | Market to Reach USD 1.97 Billion as NGS, AI-Enabled Labs, and Precision IVF Drive 12.36% CAGR

globenewswire.com
ABT Abbott Laboratories is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Abbott. AGNC Agilent Technologies, Inc. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Agilent. BKE Bio-Techne Corporation is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Bio-Techne. ILMN Illumina, Inc. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Illumina. MRK Merck KGaA is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Merck KGaA. NTRA Natera, Inc. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Natera. QGEN Qiagen N.V. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Qiagen. DGX Quest Diagnostics Incorporated is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Quest Diagnostics. TMO Thermo Fisher Scientific Inc. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards Thermo Fisher. COO The Cooper Companies Inc. is listed as a company profile in a report about the Preimplantation Genetic Testing Market. The article does not provide specific sentiment towards The Cooper Companies.

Preimplantation Genetic Testing Market - Global Forecast 2026-2032 | Market to Reach USD 1.97 Billion as NGS, AI-Enabled Labs, and Precision IVF Drive 12.36% CAGR Dublin, Nov. 19, 2026 (GLOBE NEWSWIRE) -- "Preimplantation Genetic Testing Market - Global Forecast 2026-2032" has been added to ResearchAndMarkets.com's offering.

The preimplantation genetic testing (PGT) market research report provides a comprehensive assessment of industry growth, technology adoption, clinical applications, regional dynamics, and strategic opportunities. The market is projected to reach USD 981.15 million in 2026 and expand at a CAGR of 12.36% to USD 1.97 billion by 2032. Its insights support strategic planning, competitive positioning, and market-entry decisions across fertility services, reproductive genetics, and laboratory technologies.

Market Overview and Growth Drivers

PGT is an increasingly important component of assisted reproductive technology, enabling fertility centers to assess embryos for chromosomal aneuploidy, monogenic disorders, and structural rearrangements before transfer. Key testing categories include:

Laboratory workflows are supported by next-generation sequencing (NGS), polymerase chain reaction, single-nucleotide polymorphism analysis, and whole-genome amplification. Demand is reinforced by infertility prevalence, delayed parenthood, inherited-disease awareness, and expanding access to genomic medicine. The World Health Organization estimates that approximately one in six adults experiences infertility during their lifetime.

Transformative Industry Shifts

Advances in NGS, embryo biopsy, vitrification, and integrated fertility-clinic data systems are improving testing capabilities. Trophectoderm biopsy at the blastocyst stage is widely used because it permits analysis of multiple cells while preserving the inner cell mass.

Clinical care is also shifting toward evidence-led, patient-specific planning supported by genetic counseling, laboratory accreditation, transparent reporting, and multidisciplinary review. However, mosaicism, reimbursement gaps, regulatory differences, ethical considerations, and test limitations continue to influence adoption. Understanding these constraints enables stakeholders to identify viable opportunities while mitigating clinical, regulatory, and reputational risks.

Artificial Intelligence and Digital Innovation

Artificial intelligence is emerging across embryo imaging analytics, laboratory quality control, workflow automation, and clinical decision support. Computer vision can improve consistency in embryo morphology assessment, while AI-enabled systems can monitor sample handling, flag workflow inconsistencies, and strengthen chain-of-custody controls.

Near-term value is expected to center on reducing variability, accelerating turnaround times, improving documentation, and supporting explainable decisions. Prospective validation remains essential before AI outputs can serve as standalone clinical determinants.

Regional Market Insights

Strategic Market Group and Country Perspectives

The European Union and G7 combine advanced biomedical infrastructure with established regulatory oversight. BRICS markets offer significant growth potential through large patient populations and expanding fertility networks. ASEAN adoption is supported by medical tourism hubs, while GCC countries present opportunities for PGT-M and carrier-screening-linked IVF pathways.

The United States leads in commercial availability and laboratory scale. The United Kingdom, Germany, France, Italy, and Spain remain influential European markets, while China, India, Japan, South Korea, and Australia contribute substantial clinical and technology capacity. Country-level comparisons provide practical guidance for prioritizing partnerships, investments, and localized access strategies.

Strategic Priorities for Industry Leaders

Key Takeaways from This Report

Key Attributes:

Key Topics Covered:

1. Preface

1.1. Objectives of the Study

1.2. Market Definition

1.3. Market Segmentation & Coverage

1.4. Years Considered for the Study

1.5. Currency Considered for the Study

1.6. Language Considered for the Study

1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction

2.2. Research Design

2.2.1. Primary Research

2.2.2. Secondary Research

2.3. Research Framework

2.3.1. Qualitative Analysis

2.3.2. Quantitative Analysis

2.4. Market Size Estimation

2.4.1. Top-Down Approach

2.4.2. Bottom-Up Approach

2.5. Data Triangulation

2.6. Research Outcomes

2.7. Research Assumptions

2.8. Research Limitations

3. Executive Summary

3.1. Introduction

3.2. CXO Perspective

3.3. New Revenue Opportunities

3.4. Next-Generation Business Models

3.5. Industry Roadmap

4. Market Overview

4.1. Introduction

4.2. Industry Ecosystem & Value Chain Analysis

4.2.1. Supply-Side Analysis

4.2.2. Demand-Side Analysis

4.2.3. Stakeholder Analysis

4.3. Market Dynamics

4.3.1. Key Drivers

4.3.2. Key Restraints

4.3.3. Key Opportunities

4.3.4. Key Challenges

4.4. Porter's Five Forces Analysis

4.5. PESTLE Analysis

4.6. Market Outlook

4.6.1. Near-Term Market Outlook (0-2 Years)

4.6.2. Medium-Term Market Outlook (3-5 Years)

4.6.3. Long-Term Market Outlook (5-10 Years)

4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective

5.2. Consumer Experience Benchmarking

5.3. Opportunity Mapping

5.4. Distribution Channel Analysis

5.5. Pricing Trend Analysis

5.6. Regulatory Compliance & Standards Framework

5.7. ESG & Sustainability Analysis

5.8. Disruption & Risk Scenarios

5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Preimplantation Genetic Testing Market, by Test Type

7.1. Introduction

7.2. PGT-A (Aneuploidy)

7.3. PGT-M (Monogenic Disorders)

7.4. PGT-SR (Structural Rearrangements)

7.5. PGT-HLA (Human Leukocyte Antigen Matching)

8. Preimplantation Genetic Testing Market, by Technology Type

8.1. Introduction

8.2. Comparative Genomic Hybridization

8.3. Fluorescent In-Situ Hybridization

8.4. Next-Generation Sequencing

8.5. PCR-Based Testing

8.6. Single-Nucleotide Polymorphism

9. Preimplantation Genetic Testing Market, by Offering

9.1. Introduction

9.2. Instruments

9.3. Reagents & Consumables

9.3.1. Kits

9.3.2. Probes

10. Preimplantation Genetic Testing Market, by Procedure Stage

10.1. Introduction

10.2. Embryo Biopsy

10.3. Polar Body Biopsy

10.4. Blastocyst Biopsy

11. Preimplantation Genetic Testing Market, by Application

11.1. Introduction

11.2. Aneuploidy Screening

11.3. Monogenic Diseases

11.4. IVF Prognosis

12. Preimplantation Genetic Testing Market, by End User

12.1. Introduction

12.2. Diagnostic Laboratories

12.3. Fertility Clinics

12.4. Hospitals

12.5. Research Institutes

13. Preimplantation Genetic Testing Market, by Region

13.1. Introduction

13.2. Asia-Pacific

13.3. Europe

13.4. North America

13.5. Africa

13.6. Latin America

13.7. Middle East

14. Preimplantation Genetic Testing Market, by Group

14.1. Introduction

14.2. NATO

14.3. G7

14.4. European Union

14.5. BRICS

14.6. ASEAN

14.7. GCC

15. Preimplantation Genetic Testing Market, by Country

15.1. Introduction

15.2. United States

15.3. China

15.4. Germany

15.5. Japan

15.6. India

15.7. United Kingdom

15.8. France

15.9. Australia

15.10. Canada

15.11. Italy

15.12. South Korea

15.13. Brazil

15.14. Russia

15.15. Mexico

15.16. Spain

16. Competitive Landscape

16.1. Market Share Analysis, 2025

16.2. Market Concentration Analysis, 2025

16.2.1. Concentration Ratio (CR)

16.2.2. Herfindahl Hirschman Index (HHI)

16.3. Recent Developments & Impact Analysis, 2025

16.4. Product Portfolio Analysis, 2025

16.5. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abbott Laboratories

17.2. Agilent Technologies, Inc.

17.3. Bio-Techne Corporation

17.4. Bioarray S.L.

17.5. EUROPE IVF International s.r.o.

17.6. F. Hoffmann-La Roche AG

17.7. Genea Limited

17.8. GENETiKS

17.9. Illumina, Inc.

17.10. Invicta Genetics

17.11. Invitae Corporation

17.12. Juno Genetics, US Inc.

17.13. Laboratory Corporation of America Holdings

17.14. MedGenome Labs Ltd.

17.15. Merck KGaA

17.16. Natera, Inc.

17.17. NextGen Genetics Holdings, LLC

17.18. Ovation Fertility

17.19. PacGenomics

17.20. PerkinElmer, Inc.

17.21. Progyny, Inc.

17.22. Qiagen N.V.

17.23. Quest Diagnostics Incorporated

17.24. Reproductive Genetic Innovations, LLC

17.25. SEQUENCE46, LLC

17.26. Sysmex Corporation

17.27. Takara Bio Inc.

17.28. The Cooper Companies Inc.

17.29. Thermo Fisher Scientific Inc.

17.30. Vitrolife Sweden AB

17.31. Yikon Genomics (Shanghai) Co., Ltd.

18. Key Experts

List of Figures [23]

List of Tables [298]

For more information about this report visit https://www.researchandmarkets.com/r/ccvpgc

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.